Leonhardt Ventures files patent for bioelectric diabetes reversal treatment via FABp4 regulation and Klotho regulation
Mission Viejo, California, United States, December 30, 2021 (GLOBE NEWSWIRE) – Leonhardt Ventures LLC today announced the filing of a patent application covering the controlled bioelectric down-regulation of FABp4 and up-regulation of klotho with the potential aim of reversing types 1 and 2 diabetes.
Published studies have documented that serum FABp4 levels are higher in patients with type 2 diabetes than in healthy individuals and that klotho levels are lower. Overexpression of FABp4 interferes with the ability of the pancreas and beta cells to produce healthy insulin levels. Klotho deficiency leads to decreased insulin production and increased insulin sensitivity.
Other studies have shown a correlation between abnormally low levels of FABp4 and type 1 diabetes. In these patients, moderately controlled regulatory control to return to normal, but not higher, levels may be helpful.
This new patent filing is based on the hypothesis that inhibition of FABP4 will attenuate intracellular lipid content and improve insulin signaling and insulin-stimulated glucose uptake, thus potentially reversing the effects of diabetes mellitus. type 2. Klotho supplementation increases insulin production and improves insulin sensitivity to return to normal levels (needs to be studied in well-controlled statistically significant clinical trials to prove this).
In 2017, around 462 million people were affected by type 2 diabetes, corresponding to 6.28% of the world’s population (4.4% of people aged 15-49, 15% of people aged 50 at 69 years and 22% of people aged 70 and over), for a prevalence rate of 6,059 cases per 100,000. More than one million deaths per year can be attributed to diabetes alone, making it the ninth cause of death. The burden of diabetes mellitus is increasing globally, and at a much faster rate in developed regions, such as Western Europe. The distribution between the sexes is even and the incidence peaks at around age 55. The global prevalence of type 2 diabetes is projected to increase to 7,079 people per 100,000 by 2030, reflecting a continued increase in all regions of the world. There are worrying trends of increasing prevalence in low-income countries. Urgent research in public health, clinical prevention and accelerated treatment is warranted and the Leonhardt Ventures team is committed to making its contribution.
âThe bioelectrically controlled down-regulation of FABp4 and the up-regulation of Klotho could potentially be a major breakthrough in the treatment of diabetes. This technology deserves further examination and study. Says Dr. Leslie Miller, Chief Medical Officer, Leonhardt Ventures LLC, PancreaCell LTP and Leonhardt’s Launchpads Accelerator.
Leonhardt Ventures LLC has issued, pending, pending, electing or licensed over 800 patent applications related to organ regeneration, healing and recovery. https://patents.justia.com/inventor/howard-j-leonhardt.
The Leonhardt patent and pending patents include patent claims for klotho expressing MSCs, a circulating-controlled bioelectric regulation of klotho https://patents.justia.com/patent/20200289826, bioelectric stem cell research, proliferation and differentiation control, bioelectric personalized inflammation control, bioelectric cancer treatment (10 U.S. patents issued), and bioelectric and biological organ regeneration, including pancreatic regeneration.
PancreaCell LTP a formative step The startup Leonhardt Ventures LLC has been working for years on perfecting the regeneration of the pancreas –
Another recently published study linked low klotho levels to pancreatic cancer – https://www.mdpi.com/2072-6694/13/24/6297
The Leonhardt team has already issued 10 US patents for the bioelectric treatment of cancer, including the treatment of pancreatic cancer, and has many other cancer-related patent applications pending at the USPTO, including those for modulation. klotho.
In clinical studies in Brazil, researchers sponsored by Leonhardt Ventures demonstrated an ability to increase circulating klotho by 150% in patients with kidney failure with just a few short stimulation sessions per week for 8 weeks. In our own R&D laboratories as part of preclinical studies, we obtained increased cell and tissue expressions of> 480%.
The Leonhardt team working with the startup BioLeonhardt Whole Body is developing the BodStim www.bodstim.com Stimulation combination designed to increase circulating klotho levels that are in the early stages of clinical OUS evaluation.
KlothoBios, another startup from Leonhardt Ventures, unveiled the Klotho years Klotho Blood Test – www.klothoyears.com The team working with established testing partners have successfully completed 20 test runs of this Klotho level testing system and methods and are preparing for a larger clinical study.
About Leonhardt Ventures LLC: Since 1982, the Leonhardt team has been developing and implementing medical devices and biotechnological inventions. Over 600,000 patients have been treated with Leonhardt’s inventions to date. See www.leonhardtventures.com for more information.
About PancreaCell LTP: PancreaCell is a forming-stage startup of Leonhardt Ventures LLC focused on regenerating the pancreas with a convergence of bioelectrical and biological products.
About Leonhardt Launchpads: Leonhardt’s Launchpads, founded in 2008, is the innovation and startup launch accelerator arm of Leonhardt Ventures LLC, which aims to help accelerate the development of innovation in bioelectric, biological and endovascular technologies through early studies on the man.
About CancerCell LTP: CancerCell is an early stage Leonhardt Ventures LLC startup focused on bioelectric and biological treatments for cancer, including pancreatic cancer. They have ten (10) issued patents for the treatment of bioelectric cancer and dozens of other patent applications pending with the USPTO at present. See www.cancercellinc.com
Warnings and Disclaimers: The product is not yet proven safe or effective. Forward-looking statements are subject to change without notice. Patents granted may be invalidated. Patents pending cannot be granted. Optional or licensed patents may not be maintained. The company, via an accelerator business model, shares resources in all forms between several entities. The company lacks sufficient resources to bring the products through clinical studies and to market. The company uses off-the-shelf devices and components to speed up development time where possible. Timelines are subject to change even from year or decade to decade. The company tries to do in organ regeneration what no other company or organization, even those with substantially higher resources, has ever been able to do. As an investment, this should be considered in the highest risk category for a total loss. Statistics on innovation and startup accelerators around the world indicate a blockbuster success rate of around 4% among portfolio startup entries in the top of the top accelerators. The company has a small workforce to manage over 50 websites with over 10,000 pages of documents, and it is highly likely that some pages will contain outdated information at some point. If you have specific questions, please email us for the most recent information. Priorities are constantly changing and resources are reallocated by the business design based on the acquisition interest expressed by potential buyers / strategic partners and other opportunity drivers.
Contact: Brian Hardy, Marketing Director, Email [email protected] for more information.
Media Company: Leonhardt Ventures LLC - PancreaCell LTP, Media Name: Howard J. Leonhardt, Media Phone: (424) 291-2133, Media Email: [email protected] Media URL: http://www.leonhardtventures.com/